Overview
UNCY market data
Price History
UNCY price chart · 1M
- O
- 5.47
- H
- 5.52
- L
- 5.45
- C
- 5.47
- Vol
- 16,221.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.47
- Previous Close
- $5.43
- Day High
- $5.52
- Day Low
- $5.45
- 52 Week High
- $8.74
- 52 Week Low
- $3.99
- 7 Day Return
- +0.46%
- 30 Day Return
- +10.84%
- 90 Day Return
- -25.68%
- 1 Year Return
- -23.60%
- Daily Notional Volume
- $88.7K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.48 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.76 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -4,159.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.71 – $8.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $137.2M · P/B 4.11 · P/S 31.15.
Company News
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15Benzinga · Aug 20, 2026, 3:38 PM
Guggenheim Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $25Benzinga · Aug 13, 2026, 2:12 PM
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20Benzinga · Aug 13, 2026, 1:56 PM
8-K filing — Unicycive Therapeutics, Inc. (UNCY)SEC EDGAR · Aug 12, 2026, 12:04 PM
Unicycive Therapeutics Q2 EPS $(0.06) Beats $(0.34) EstimateBenzinga · Aug 12, 2026, 10:43 AM
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading WarningsBenzinga · Jul 16, 2026, 5:29 PM
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud InvestigationGlobenewswire Inc · Jul 13, 2026, 7:15 PM
ALHC ALERT: Block & Leviton Investigating Alignment Healthcare, Inc. For Possible Securities Fraud; Investors Should Contact Block & Leviton to Learn MoreGlobenewswire Inc · Jul 8, 2026, 10:15 PM
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Lowers Price Target to $13Benzinga · Jul 1, 2026, 3:40 PM
Noble Capital Markets Maintains Outperform on Unicycive Therapeutics, Lowers Price Target to $50Benzinga · Jul 1, 2026, 2:00 PM